non-small cell lung cancer
Conditions
Interventions
Part1:no intervention
Part 2 PD-L1>= 50%:with or without chemotherapy
Part 2 PD-L1< 50%:with or without chemotherapy
Sponsors
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Stage III and IV non-small cell lung cancer confirmed by histopathology or cytology and determined by the investigator to be unresectable (International Association for the Study of Lung Cancer Eighth Edition Lung Cancer Staging). 2. Patients have not received first-line anti-tumor systemic therapy 3. The Eastern Cooperative Oncology Group (ECOG) physical status score is 0 or 1; 4. The physical condition and organ function allow to carry out anti-tumor systemic treatment, including standard chemotherapy and immunopharmaceutical treatment; 5. There is imaging to assess the lesion of tumor; 6. Patients with brain metastases are asymptomatic or have stable symptoms with local treatment; 7. The patients' age are over 18 years old when signs the informed consent form; 8. Blood samples and/or tumor tissue samples ,immune microenvironment-related multicolor immunofluorescence histochemical test results had collected before the start of first-line treatment NGS; 9. The patient has the ability to follow the planned schedule and actively cooperate with returning to the hospital for regular clinical follow-up and necessary treatment; 10. Patients who can provide the clinical data needed for research, and is willing to use the test data for further scientific research and commercial product development.
Exclusion criteria
Exclusion criteria: 1. Patients suffered from other active malignant tumors within 5 years before enrollment. Cured localized tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, etc. can be included in the group; 2. Advanced NSCLC patients who have previously received systemic anti-tumor therapy and have no baseline blood sample NGS test results 3. As judged by the investigator, patients who also suffer from other serious diseases that may affect follow-up and/or significantly shorten survival; 4. Patients who are accompanied by any other medical conditions and social/psychological problems, etc., who are judged by the investigator to be unsuitable to participate in this study; 5. Patients who cannot accept the use of contrast-enhanced magnetic resonance imaging (MRI) or contrast-enhanced computed tomography (CT) for clinical follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| circulating tumor DNA;Programmed cell death 1 ligand 1; | — |
Secondary
| Measure | Time frame |
|---|---|
| basic vital signs; | — |
Countries
China
Contacts
Public ContactXiang Yi
Shanghai Jiao Tong University School of Medicine
Outcome results
None listed